Witt Caitlin E, Sutton Elizabeth F, Stansbury Ashley M, Winters Ashley N, Konur Luke C, Luo Meng, Cameron Jennifer E, Ogden Beverly
Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, New Orleans, LA.
Department of Research, Woman's Hospital, Baton Rouge, LA.
Ochsner J. 2024 Fall;24(3):179-183. doi: 10.31486/toj.24.0018.
The objective of this study was to determine the human papillomavirus (HPV) genotypes of high-risk-other HPV Papanicolaou (Pap) tests and of biopsy tissues from patients with high-grade squamous intraepithelial lesion (HGSIL) or cervical cancer. High-risk-other HPV status was determined with the cobas HPV Test (Roche Diagnostics, North America) that identifies 12 high-risk, non-16/18 HPV genotypes. We hypothesized that we would find genotypes of HPV in our population that are not covered by the 9-valent HPV vaccine. For this retrospective cohort study, we randomly selected 50 high-risk-other HPV Pap test samples from 2018 from our pathology department registries for HPV genotype determination by Roche Linear Array (Roche Diagnostics, North America). Then we randomly selected 76 cervical biopsy samples of HGSIL or cervical cancer with high-risk-other HPV or HPV unknown status from 2016 to 2022 for HPV genotype determination by next-generation sequencing. Results are reported as counts and frequencies. In the 50 high-risk-other HPV Pap test samples, 21 genotypes of HPV were noted; the most common were 53 (n=6), 51 (n=6), and 59 (n=5). In the samples with HGSIL or cervical cancer, 16 HPV genotypes were detected; the most common were 16 (n=26), 58 (n=12), and 33 (n=8). Among the patients with HGSIL or cervical cancer, the 9-valent HPV vaccine provided coverage for all the HPV variants found in 88% of patients, partial coverage in 8% of patients, and no coverage in 4% of patients. The 3 most common HPV genotypes seen in our high-risk-other HPV Pap test samples are not covered by the 9-valent HPV vaccine. For the HGSIL and cancer samples, 88% of the samples had full HPV genotype coverage with the 9-valent HPV vaccine. This study highlights a presence of HPV that will not be protected by vaccination in a high-risk population.
本研究的目的是确定高危型其他人类乳头瘤病毒（HPV）巴氏试验以及高级别鳞状上皮内病变（HGSIL）或宫颈癌患者活检组织中的HPV基因型。使用cobas HPV检测（罗氏诊断，北美）确定高危型其他HPV状态，该检测可识别12种高危、非16/18型HPV基因型。我们假设在我们的人群中会发现9价HPV疫苗未涵盖的HPV基因型。对于这项回顾性队列研究，我们从病理科登记处随机选取了2018年的50份高危型其他HPV巴氏试验样本，通过罗氏线性阵列（罗氏诊断，北美）进行HPV基因型测定。然后，我们从2016年至2022年随机选取了76份HGSIL或宫颈癌的宫颈活检样本，这些样本具有高危型其他HPV或HPV状态未知，通过下一代测序进行HPV基因型测定。结果以计数和频率报告。在50份高危型其他HPV巴氏试验样本中，发现了21种HPV基因型；最常见的是53型（n = 6）、51型（n = 6）和59型（n = 5）。在HGSIL或宫颈癌样本中，检测到16种HPV基因型；最常见的是16型（n = 26）、58型（n = 12）和33型（n = 8）。在HGSIL或宫颈癌患者中，9价HPV疫苗为88%的患者中发现的所有HPV变异株提供了覆盖，为8%的患者提供了部分覆盖，为4%的患者未提供覆盖。在我们的高危型其他HPV巴氏试验样本中看到的3种最常见的HPV基因型未被9价HPV疫苗涵盖。对于HGSIL和癌症样本，88%的样本通过9价HPV疫苗实现了完整的HPV基因型覆盖。这项研究突出了高危人群中存在不会因接种疫苗而得到保护的HPV。
